MabCure, Inc. Study Results on a New Ovarian Cancer Diagnostic Blood Test Being Presented at the Annual Meeting of the Society of Gynecological Oncologists

Published: Mar 08, 2011

ORLANDO, Fla.--(BUSINESS WIRE)--Biotechnology company MabCure, Inc. (OTCBB: MBCI) is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists (SGO).

Back to news